ArticleCureus2025
Spotlight on Perfusion: Reshaping Oropharyngeal Squamous Cell Carcinoma Surgery.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oropharyngeal squamous cell carcinoma (OPSCC), commonly referred to as throat or tonsil cancer, is a type of head and neck malignancy arising from the base and posterior third of the tongue, tonsils, soft palate, and posterolateral pharyngeal walls. Standard treatment typically involves a single modality or a combination of surgery, radiotherapy, and/or chemotherapy. Despite favorable oncologic outcomes, chemoradiation is associated with considerable acute and long-term toxicities, including treatment-related mortality, debilitating dysphagia, fibrosis, severe xerostomia, and an increased risk of secondary malignancies. In this context, fluorescence-guided surgery (FGS) has emerged as a promising, minimally invasive intraoperative tool for OPSCC surgery. By leveraging indocyanine green (ICG), FGS offers enhanced visualization and real-time tissue differentiation, facilitating precise tumor resection and reducing the risk of surgical complications. This case presents an 83-year-old female patient who underwent radical OPSCC resection followed by complex reconstructive surgery utilizing a novel near-infrared FGS device.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.